Economic burden of relapsed/refractory chronic lymphocytic leukemia.

被引：2
|
作者：
Guerin, Annie
Ray, Saurabh
Gauthier, Genevieve
Hsu, Ling-I
Zhdanava, Maryia
Heroux, Julie
Wu, Eric Qiong
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] AbbVie, N Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e18065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18065
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Lesley J. Scott
    Targeted Oncology, 2019, 14 : 493 - 504
  • [22] Update on the management of relapsed/refractory chronic lymphocytic leukemia
    Rory Bennett
    John F. Seymour
    Blood Cancer Journal, 14
  • [23] Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia
    Scott, Lesley J.
    TARGETED ONCOLOGY, 2019, 14 (05) : 493 - 504
  • [24] Economic Analysis of Alemtuzumab in Fludarabine-Refractory and Relapsed Chronic Lymphocytic Leukemia in Canada
    Isogai, Pierre K.
    Cheung, Matthew
    Mittmann, Nicole
    BLOOD, 2008, 112 (11) : 827 - 827
  • [25] Ofatumumab in combination with high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.
    Castro, Januario E.
    Choi, Michael Y.
    Carvajal, Tomas
    Li, Hongying
    James, Danelle Frances
    Messer, Karen
    Kipps, Thomas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Network meta-analysis of progression free survival in the treatment of relapsed or refractory chronic lymphocytic leukemia.
    Chanan-Khan, Asher
    Liu, Tom
    Yang, Keri
    Cohen, Aileen
    Fahrbach, Kyle
    Campbell, Joanna
    Tang, Boxiong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] The Combination of Lenalidomide and Rituximab Induces Complete and Partial Responses In Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia.
    Ferrajoli, Alessandra
    Badoux, Xavier
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lerner, Susan
    Kantarjian, Hagop
    Keating, Michael J.
    BLOOD, 2010, 116 (21) : 600 - 600
  • [28] Chronic lymphocytic leukemia.
    Andritsos L.
    Khoury H.
    Current Treatment Options in Oncology, 2002, 3 (3) : 225 - 231
  • [29] Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    Seymour, J. F.
    Kipps, T. J.
    Eichhorst, B.
    Hillmen, P.
    D'Rozario, J.
    Assouline, S.
    Owen, C.
    Gerecitano, J.
    Robak, T.
    De la Serna, J.
    Jaeger, U.
    Cartron, G.
    Montillo, M.
    Humerickhouse, R.
    Punnoose, E. A.
    Li, Y.
    Boyer, M.
    Humphrey, K.
    Mobasher, M.
    Kater, A. P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (12): : 1107 - 1120
  • [30] UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA.
    Piris-Villaespesa, M.
    Chavez, J.
    Dalia, S.
    Veliz, M.
    Lancet, Jeffrey
    Bello, C.
    Turba, E.
    Shah, B.
    Komrokji, R.
    Sokol, L.
    Locke, F.
    Kharfan-Dabaja, M.
    Sotomayor, E.
    Pinilla-Ibarz, J.
    HAEMATOLOGICA, 2013, 98 : 46 - 46
12345